Skip to main content
OpenTrials
Completed

NCT Number: NCT03075241

Z-Drugs for Sleep Disorders in Alzheimer's Disease

The purpose of this study is to determine whether Zolpidem and Zoplicone are efective in the treatment of sleep disorders in Alzheimer's disease (AD)

Completed

Looking for future studies?

Notify Me

Key information

About this study

Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make caring for patients at home very difficult. Zolpidem and Zoplicone are prescribed drugs for sleep disorder in AD patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 55 years of age or older
  • Diagnosis of probable Alzheimer's disease (AD) by National Institute of Neurological and Communicative Disorders and Stroke / the Alzheimer's Disease and Related Disorders Association Criteria
  • Hachinski Ischemia Scale less than 5
  • Mini-Mental State Examination score of 0 to 26
  • Actigraph evidence of a mean time immobile of less than 7 hours per night based on at least 7 nights of complete actigraph data collected over a single week
  • Four-week history of sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver using the Neuropsychiatric Inventory (NPI) Nighttime Behavior scale
  • Sleep disturbance observed was not present before the diagnosis of AD
  • Other co-morbidities, especially delirium, depression, chronic pain and medication use may be present, but do not cooperate in the primary symptoms
  • Computed tomography or magnetic resonance imaging since the onset of memory problems showing no more than 1 lacunar infract in a nonstrategic area and no clinical events suggestive of stroke or other intracranial disease or normal
  • Stable medications for 4 weeks prior to the screening visit
  • Having a mobile upper extremity to which to attach an actigraph
  • Residing with a responsible spouse, family member, or professional caregiver who is present during the night and would agree to assume the role of the principle caregiver for the 3-week protocol
  • Ability to ingest oral medication and participate in all scheduled evaluations

Exclusion criteria

  • Sleep disturbance associated with an acute illness, delirium or psychiatric disease
  • Clinically significant movement disorder, such as akinesia, that would affect actigraphic differentiation of sleep and wakefulness
  • Severe agitation
  • Unstable medical condition
  • Discontinuation of psychotropic or sleep medication within 2 weeks of the screening visit
  • Patient unwilling to maintain caffeine abstinence after 2:00pm for the duration of the protocol
  • Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, and only 1 alcoholic drink after 6:00pm for the duration of the protocolo
  • Prior use of zolpidem/zoplicone for the treatment os sleep disturbances
  • Caregiver deemed to be unreliable to supervise the wearing of the actigraph, to administer study capsules at the proper time, to maintain the sleep diary, or to bring the patient to the scheduled visits

Treatment and study plan

zolpidem

Drug

Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights

Zoplicone

Drug

Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights

Placebo

Drug

Inactive or inert pill which will be used as a comparator

Primary outcomes

  1. Nighttime Total Sleep Time

    Time frame: Baseline, 14 days follow-up

    Mean Total Sleep Time (in minutes) during the 12h nocturnal period (8:00pm-8:00am) after 2 weeks under treatment

Secondary outcomes

  1. Daytime Total Sleep Time

    Time frame: Baseline, 14 days follow-up

    Daytime Total Sleep Time (in minutes) during the 12h daytime period (8:00am-8:00pm) after 2 weeks under treatment

  2. Ratio of daytime to nighttime sleep

    Time frame: Baseline, 14 days follow-up

    Daytime Total Sleep Time / Nighttime Total Sleep Time

  3. Nighttime Wake after Sleep Onset

    Time frame: Baseline, 14 days follow-up

    Nighttime Wake after Sleep Onset (in minutes) during the 12h nocturnal period (8:00pm-8:00am) after 2 weeks under treatment

  4. Proportion of sleep time at nighttime

    Time frame: Baseline, 14 days follow-up

    Proportion of sleep time (%) during the 12h nocturnal period (8:00pm-8:00am) after 2 weeks under treatment

  5. Proportion of patients with gain of at least 30 minutes in Total Sleep Time

    Time frame: Baseline, 14 days follow-up

    Proportion of patients with gain of at least 30 minutes in Total Sleep Time after 2 weeks under treatment

  6. Differences between sleep efficiency between the two treatments.

    Time frame: Baseline, 14 days follow-up

    Analyze possible differences between sleep efficiency between the two treatments after 2 weeks under treatment

  7. Nighttime Number of Awakenings

    Time frame: Baseline, 14 days follow-up

    Change in scores of nighttime number of awakenings from baseline to intervention weeks

Sponsors and collaborators

Lead sponsor

Brasilia University Hospital

Other

Registry information

Official study title

Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Triple-blind, Placebo-controlled Study

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Mar 9, 2017
Registry last updated
Nov 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.